Trxade Group Inc Stock

$0.89

4.64%

Nasdaq, Sep 05, 10:07 pm CET

ISIN

US89846A2078

Symbol

SCNX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Technology

Overview Dividends Analysts Charts News Strategies

Trxade Group Inc Stock price

$0.89

-52.05 98.33% 5Y

Nasdaq, Closing price Fri, Sep 05 2025

-0.04 4.64%

ISIN

US89846A2078

Symbol

SCNX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Technology

Key metrics

Basic

Market capitalization

$18.4m

Enterprise Value

$22.5m

Net debt

$4.1m

Cash

$20.0k

Shares outstanding

16.1m

Valuation (TTM | estimate)

P/E

negative | -

P/S

141.5 | -

EV/Sales

172.9 | -

EV/FCF

negative

P/B

0.2

Dividends

DPS

$8.96

Yield 1Y | 5Y

0.0% | 0.0%

Growth 1Y | 5Y

- | -

Payout 1Y | 3Y

361.5% | -33.1%

Increased

1 Year

Financials (TTM | estimate)

Revenue

$130.0k | -

EBITDA

$-16.4m | -

EBIT

$-16.4m | -

Net Income

$-20.1m | -

Free Cash Flow

$-13.3m

Growth (TTM | estimate)

Revenue

-97.1% | -

EBITDA

14.6% | -

EBIT

14.2% | -

Net Income

-582.7% | -

Free Cash Flow

-35.7%

Financial Health

Equity Ratio

75.4%

Return on Equity

11.5%

ROCE

-17.0%

ROIC

-15.9%

Debt/Equity

0.1

EPS

$-1.4

FCF per Share

$-0.8

Short interest

1.9%

Employees

Rev per Employee

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Get Started for Free Today

Trxade Group Inc Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Trxade Group Inc forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Trxade Group Inc forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Trxade Group Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	0.13 0.13	97% 97% 100%
- Direct Costs	0.12 0.12	98% 98% 92%
Gross Profit	0.01 0.01	102% 102% 8%
- Selling and Administrative Expenses	13 13	5% 5% 9,838%
- Research and Development Expense	3.65 3.65	- 2,808%
EBITDA	-16 -16	15% 15% -12,585%
- Depreciation and Amortization	0.08 0.08	700% 700% 62%
EBIT (Operating Income) EBIT	-16 -16	14% 14% -12,647%
Net Profit	-20 -20	583% 583% -15,485%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Trxade Group Inc Stock News

Neutral

GlobeNewsWire

●

24 days ago

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (Nasdaq: SCNX) (“Scienture” or the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announ...

Neutral

GlobeNewsWire

●

25 days ago

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the shipment of launc...

Neutral

GlobeNewsWire

●

about 2 months ago

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that its boa...

More Trxade Group Inc News

Company Profile

Trxade Group, Inc. owns and operates a business-to-business Web-based marketplace focused on the pharmaceutical industry in the United States. It operates through Trxade, Inc.; Community Specialty Pharmacy, LLC; and Other segments. The company operates a Web based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories, and services. Its principal products and services include Trxade.com, a Web-based pharmaceutical marketplace; InventoryRx.com, a Web-based pharmaceutical exchange platform; Pharmabayonline that provides proprietary pharmaceutical data analytics and governmental reimbursement benchmarks analysis to the United States-based independent pharmacies and pharmaceutical databases; and RxGuru, a desktop application, which provides product information. The company also operates a retail specialty pharmacy. In addition, it operates Delivmeds.com, a consumer-based app to provide delivery of pharmaceutical products; and Trxademso.com to assist independent retail pharmacies on pricing, distribution, and logistics. Trxade Group, Inc. is based in Land O'Lakes, Florida.

Head office	United States
CEO	Surendra Ajjarapu
Founded	2005
Website	www.trxadehealth.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now